AI and Robotics Revolutionize Drug Discovery with New Funding

Excelsior Sciences has raised seventy million dollars in a Series A funding round led by Khosla Ventures and other investors. The company aims to leverage artificial intelligence and robotics for the discovery and development of small-molecule drugs.

This funding highlights the increasing significance of AI and robotics in drug discovery, potentially accelerating medical advancements and leading to innovative treatments for various diseases.